Antithrombin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Usage, By Source, By Type, By Region & Competition, 2021-2031F

The Global Antithrombin Market is projected to expand from USD 793.11 Million in 2025 to USD 1082.43 Million by 2031, registering a CAGR of 5.32%. As a vital liver-produced glycoprotein, antithrombin acts as a key natural anticoagulant by neutralizing serine proteases like thrombin and Factor Xa within the coagulation system. Market growth is largely driven by improved diagnosis of hereditary antithrombin deficiency and the critical need for effective anticoagulation during complex surgical procedures, such as cardiopulmonary bypass operations. The urgency for specialized therapies is highlighted by the limitations of standard treatments; registry data cited by the International Society on Thrombosis and Haemostasis in 2024 revealed that recurrent thrombosis affected 58.6% of patients with hereditary deficiency despite conventional anticoagulation, emphasizing the clinical necessity for dedicated antithrombin replacement products.

However, market expansion is hindered by the significant costs and restricted availability associated with plasma-derived therapeutics, which limit access within budget-constrained healthcare systems. Antithrombin production depends heavily on human plasma fractionation, a process strictly bound by donor availability and rigorous safety protocols. This reliance on a variable biological raw material introduces supply chain vulnerabilities and drives up manufacturing costs, ultimately curbing market penetration in developing regions where financial constraints often force healthcare providers to rely on alternative, less expensive standard-of-care anticoagulants.

Market Driver

The increasing global incidence of Venous Thromboembolism (VTE) and coagulation disorders acts as a major catalyst for market growth, necessitating strong therapeutic interventions for high-risk populations. With thrombotic events rising worldwide-especially among those with hereditary antithrombin deficiency or undergoing complex surgeries where standard heparin is inadequate-the demand for specialized replacement therapies has surged. This elevated clinical need is evident in the financial results of leading manufacturers; for instance, Grifols reported in February 2025 that its Biopharma unit saw a 15.1% revenue increase in the fourth quarter of 2024, a performance the company explicitly linked to robust global demand for plasma proteins.

Concurrently, the market is benefiting from the improved availability of plasma-derived antithrombin concentrates, which is addressing past supply chain issues and enabling reliable patient access. Market stability depends on efficient human plasma collection and fractionation, areas where key industry players have optimized operations and expanded capacity. Reflecting this progress, Kedrion Biopharma reported in April 2025 a fiscal year turnover of 1.578 billion Euros-a 10% increase driven by its plasma-derived portfolio. This growth is supported by strict safety standards that ensure a sustainable supply; the Plasma Protein Therapeutics Association noted in February 2025 that adverse events occur in only 0.16% of donations, confirming the safety protocols necessary to maintain the donor base essential for antithrombin production.

Market Challenge

A significant obstacle to the Global Antithrombin Market is its reliance on human plasma fractionation, as plasma-derived therapies depend on a finite biological resource that cannot be rapidly scaled to match rising clinical needs. This limitation is exacerbated by the industry's dependence on specific collection regions, leading to supply chain fragility. According to 2025 data from the Plasma Protein Therapeutics Association, North America provided over 63% of the global plasma utilized for manufacturing, highlighting a severe geographic concentration of raw material. Consequently, any interruption in this primary source region immediately affects global availability, threatening consistent product delivery and restricting revenue opportunities.

Furthermore, the intricate manufacturing processes necessary to guarantee viral safety and product purity involve high operational costs. These expenses translate into elevated pricing structures that restrict product accessibility in cost-sensitive healthcare markets. In developing regions with limited budgets, medical providers frequently opt for lower-cost, non-specific anticoagulants instead of specialized antithrombin treatments. This economic barrier directly hinders market penetration and blocks the widespread adoption of antithrombin therapies in emerging economies, effectively limiting the market's overall global growth potential.

Market Trends

The increasing use of Extracorporeal Membrane Oxygenation (ECMO) protocols is altering market demand, as clinicians frequently turn to antithrombin supplementation to manage heparin resistance in critically ill patients. Standard anticoagulation often proves insufficient during prolonged extracorporeal support because natural antithrombin is rapidly consumed, requiring exogenous replacement to maintain circuit patency and prevent dangerous thrombosis. This integration into advanced life support creates a direct link between therapeutic consumption and the rising use of mechanical circulatory support; the Extracorporeal Life Support Organization reported in April 2025 that cumulative global registry volume hit 245,291 ECMO runs, demonstrating a strong upward trend that requires reliable adjunct anticoagulation.

Simultaneously, the market is expanding its clinical scope into sepsis and trauma care, positioning antithrombin as a dual-action therapy that utilizes its anti-inflammatory properties to manage coagulopathy in septic shock. Industry stakeholders are actively seeking label expansions to treat disseminated intravascular coagulation, aiming to elevate the biologic from a niche orphan drug to a mainstream critical care treatment. This strategy addresses a massive unmet medical need; as highlighted by the Global Sepsis Alliance in July 2025, sepsis causes approximately one in five deaths worldwide, representing a vast patient population that could significantly increase the addressable market for plasma-derived therapies.

Key Market Players

• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion S.p.A

Report Scope

In this report, the Global Antithrombin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antithrombin Market, By Usage

• Therapeutics
• Diagnostics
• Research
• Others

Antithrombin Market, By Source

• Human
• Recombinant Goat Milk
• Others

Antithrombin Market, By Type

• Anticoagulant
• Antiplatelet
• Thrombolytic Drugs

Antithrombin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin Market.

Available Customizations:

Global Antithrombin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).